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Aim To investigate the association between depression, 
metabolic syndrome (MBS), somatic, particularly cardiovas-
cular comorbidity, and low-grade chronic inflammation as-
sessed using C-reactive protein (CRP).
Methods This cross-sectional study included 76 patients 
with recurrent depressive disorder (RDD) and 72 non-de-
pressed medical staff controls from the Department of Psy-
chiatry, University Hospital Center Zagreb between Janu-
ary 2011 and June 2012.
Results Seventy-five percent of patients had somatic co-
morbidity. The most common comorbid conditions were 
cardiovascular disorders (46.1%), locomotor system diseas-
es (35.5%), carcinoma (15.8%), thyroid diseases (9.2%), and 
diabetes (9.2%). MTB was more common in RDD patients 
(31.6%) than in controls (23.6%), but the difference was 
not significant. Elevated CRP was found to be significantly 
more frequent in patients with recurrent depressive disor-
ders (RDD) (35.5%; χ2 test, P = 0.001, Cramer V = 0.29) than 
in controls (12.5%) and was associated with lowered high-
density lipoprotein and overweight/obesity.
Conclusion We found some intriguing links between 
stress, depression, metabolic syndrome, and low grade 
inflammation, which may be relevant for the prevalence 
of somatic comorbidity in patients with RDD, but further 
studies are needed to confirm our results.
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Depression and somatic, particularly cardiovascular disor-
ders, are closely interrelated, which is why it is important 
to study depression, metabolic syndrome, and somatic 
comorbidity together. Depressed mood is recognized to 
contribute to the development and progression of some 
somatic, especially cardiovascular diseases, while cardio-
vascular and some other somatic diseases may increase 
the risk of depression. In spite of a considerable progress 
in comorbidity research, this phenomenon is one of the 
greatest epistemological, research, and clinical challenges 
to contemporary psychiatry and medicine (1,2). In clini-
cal practice, comorbidity is underrecognized, underdiag-
nosed, underestimated, and undertreated. The definition 
of comorbidity and multisystem disorder is also not very 
clear. Do depression, diabetes, and coronary heart disease 
represent comorbid disorders or a multisystem mind-body 
disease (2)? In addition to high rates of somatic comorbid-
ity, depression is characterized with high rates of metabol-
ic, oxidative stress, and pro-inflammatory risk-factors. The 
relationship of depression with future coronary heart dis-
ease (CHD) has been a important research topic over the 
last 20 years and has provoked much thought on the link 
between the mind, brain, and heart (3,4).
Metabolic syndrome (MBS) characterized by metabol-
ic abnormalities, such as abdominal obesity, high blood 
pressure, hyperglycemia, low high density lipoprotein 
(HDL) cholesterol, and elevated triglycerides is an im-
portant risk factor for CHD and type 2 diabetes mellitus 
(DM). Depression, which is also an independent risk fac-
tor for CHD and DM type 2, is frequent in individuals with 
MBS (5), and MBS is more common in depressed patients 
than in general population (6). However, it is still not clear 
whether and to what extent MBS is a significant mediator 
in the depression-CHD comorbidity. Therefore, the MBS-
depression relationship is of significant scientific and pub-
lic health interest.
Growing evidence indicates that low grade chronic in-
flammation may be associated with MBS and coronary 
heart disease (5), as well as with depression (7), but the 
exact nature of this relationship is still unknown (8). De-
pression is often characterized with high levels of C-reac-
tive protein (CRP), which may contribute to cardiovascu-
lar disease development in depressed patients without 
somatic diseases (7). On the other hand, elevated CRP 
levels are significantly correlated with oxidative stress 
markers and an increased risk of MBS, and individuals 
with MBS may have a higher inflammation status and 
a higher level of oxidative stress.
The aim of this study was to investigate the prevalence of 
somatic, particularly cardiovascular comorbidity, and MBS 
and its components in patients with recurrent major de-
pression, as well as the prevalence of increased CRP as an 
additional comorbidity risk factor. This report has been part 
of a bigger multidimensional study, which includes many 
other parameters like cortisol, cathecholamines, homo-
cisteine, methylenetetrahydrofolate reductase polymor-
phism, HbA1C, ECG, as well as A/B and D personality types.
PaRTiciPanTs anD MeThoDs
Participants
The sample comprised 148 participants, 76 patients with 
recurrent depressive disorder (without psychotic features) 
and 72 controls (medical staff ). The study was conducted 
at the Department of Psychiatry, University Hospital Cen-
ter Zagreb, between January 2011 and June 2012. Diagno-
sis of recurrent depressive disorder was established by the 
ICD-10 and DSM IV criteria by the attending psychiatrist. 
The mean age of the participants was 50.98 ± 8.4 years, 
51.42 ± 8.5 years in patients with depression and 50.51 ± 8.3 
years in controls. The groups did not differ in age and sex. 
Written informed consent was obtained from all partici-
pants. The study protocol was approved by the Ethics 
Committee of the University Hospital Center, Zagreb.
Measures
Sociodemographic and anamnestic questionnaire. So-
ciodemographic and anamnestic questionnaire was de-
signed for the purpose of this study to assess the following 
variables: age, sex, education, employment, marital status, 
number of children in family, onset of illness, personal so-
matic anamnesis, psychiatric heredity and comorbidity, 
consumption of alcohol, and cigarette smoking.
Biological parameters – metabolic syndrome and CRP. MS 
was defined according to NCEP ATP III criteria (National In-
stitute of Health, Third Report of the National Cholesterol 
Education Program Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults), which 
require that three or more of the following five criteria are 
present: 1) increased waist circumference: >88 in women 
or 102 in men; 2) elevated triglycerides: ≥1.7 mmol/L; 3) 
reduced high-density lipoprotein (HDL) cholesterol: <1.03 
mmol/L in men or <1.29mmol/L in women; 4) elevated 
blood pressure: ≥130/85 mm/Hg; 5) elevated fasting glu-
cose: ≥5.6 mmol/L.
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Waist circumference was measured by tape measure and 
blood pressure was determined by pressure gauge. Veni-
puncture was performed every morning after 12 hours 
of overnight fasting. After collection, blood samples were 
delivered to the central laboratory and serum concentra-
tion of triglycerides, total cholesterol, HDL cholesterol, low 
density lipoprotein cholesterol (LDL-c), and serum glucose 
were determined using enzyme methods and commercial 
kits (Olympus Diagnostic, GmbH, Hamburg, Germany) on 
Olympus AU 600 automated analyzer. CRP serum levels 
were determined using immunoturbidimetric method on 
Olympus AU 2700. The cut-off point for elevated CRP was 
set at 5 mg/L.
statistical analysis
Normality of distribution of Framingham score results was 
tested by Kolmogorov-Smirnov test. Results are present-
ed as medians and interquartile ranges. Differences be-
tween two groups in continuous variables were tested us-
ing Mann-Whitney test, with area under the curve (AUC) 
given as the standardized measure of size effect. AUC was 
calculated according to the formula: U/(m × n), where U 
is the result of the Mann-Whitney test, m and n are sizes 
of two samples. Differences between nominal variables 
were analyzed by χ2 test, with Cramer V as the standard-
ized measure of size effect. Fisher exact test was used for 
analysis of two dichotomous variables, with Cramer V as 
the standardized measure of size effect. To test simultane-
ous occurrence of key metabolic risk factors, Jaccard simi-
larity measure was used. The level of significance was set 
to P < 0.05, with 95% confidence intervals. All the analyses 
were carried out using SPSS 17.0 (SPSS Inc., Chicago, IL, 
USA) statistical software package.
ResuLTs
Significantly more patients with RDD than controls had a 
physical disease (75.0% vs 19.4%; χ2 test, P < 0.001, Cramer 
V = 0.56). There were also significantly more RDD patients 
than controls with diseases of locomotor system (35.5% vs 
6.9%; χ2 test, P < 0.001, Cramer V = 0.35), as well as carcinoma 
(25.8% vs 1.4%; χ2 test, P = 0.002, Cramer V = 0.25), diabetes 
(9.2% vs 0%; χ2 test, P = 0.014, Cramer V = 0.22), and dyslipi-
demia (7.9% vs 0%; χ2 test, P = 0.028, Cramer V = 0.2). Signifi-
cantly more RDD patients (46.1%) than controls had some CV 
disease (13.9%) (χ2 test, P < 0.001, Cramer V = 0.35) (Table 1).
Significantly more RDD patients with elevated CRP (37%) 
than RDD patients with normal CRP had lowered HDL 
(14.3%) (χ2 test; P = 0.042; Cramer V = 0.26). There was no 
significant difference in these parameters among controls 
(Table 2).
Obesity was significantly more common among partici-
pants with elevated CRP in both RDD (χ2 test, P < 0.003; Cra-
mer’s V = 0.40) and control groups (χ2 test; P < 0.033; Cram-
er’s V = 0.31) (Table 2).
Significantly more RDD patients with elevated CRP (48.1%) 
than RDD patients with normal level of CRP (22.4%) had 
MBS (χ2 test; P = 0.038; Cramer’s V = 0.27). MBS was also 
TabLe 1. Physical and cardiovascular diseases by groups
experimental 
group
control 
group
n % n % P; effect
Physical diseases*
diseases of the 
locomotor system
27  35.5  5   6.9 <0.001; 0.347
carcinoma 12  15.8  1   1.4  0.002; 0.254
thyroid disease  7   9.2  4   5.6  0.535
diabetes  7   9.2  0.014; 0.217
gastritis/ulcer  4   5.3  2   2.8  0.682
dyslipidemia  6   7.9  0.028; 0200
osteoporosis  2   2.6  0.497
dermatitis  2   2.6  0.497
anemia  1   1.3 >0.999
asthma  1   1.3 >0.999
other 20  26.3  3   4.2 <0.001; 0.306
no diseases 19  25.0 58 80.6
cardiovascular 
diseases*
yes 35  46.1 10  13.9 <0.001; 0.349
no 41  53.9 62  86.1
total 76 100 72 100
number of diseases†
none 19  25.0 58  80.6 <0.001; 0.19
one 32  42.1 13  18.1
two 20  26.3  1   1.4
three  3   3.9
four  2   2.6
total 76 100 72 100
any physical disease*
yes 57  75.0 14  19.4 <0.001; 0.556
no 19  25.0 58  80.6
total 76 100 72 100
*Fisher exact test; level of statistical significance or probability of Type 
i error; effect = cramer V given as the effect size for χ2 test, only for 
significant results.
†Mann-Whitney u test for number of diseases, effect = area under the 
curve (auc) as the effect size for Mann-Whitney test.
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more frequent in controls with elevated CRP level, but the 
difference was not significant (Table 3) (Figure 1).
To check for simultaneous occurrence of key metabolic risk 
factors, Jaccard similarity measure was used. The highest 
rate of simultaneous occurrence was found among blood 
lipids: Jaccard similarity measure for elevated total choles-
terol and elevated LDL was 0.81 and for tryglicerides and 
total cholesterol 0.54. CRP and BMI also showed a some-
what higher similarity measure (0.41).
TabLe 2. Differences in metabolic disorders and metabolic syndrome prevalence by c reactive protein (cRP)
Recurrent depressive disorders (RDD) group control group
elevated cRP normal cRP elevated cRP normal cRP
n % n % P; effect n % n % P; effect
hypertension (>80, 135 mm hg)*
no 14  51.9 35  71.4 0.132  6  66.7 42  66.7 >0.999
yes 13  48.1 14  28.6  3  33.3 21  33.3
total 27 100 49 100  9 100 63 100
hyperglycemia *
no 20  74.1 40  81.6 0.558  5  55.6 53  84.1 0.065
yes (>6.1)  7  25.9  9  18.4  4  44.4 10  15.9
total 27 100 49 100  9 100 63 100
cholesterol*
normal 10  37.0 11  22.4 0.191  0   0.0 12  19.0 0.340
elevated (>5.0) 17  63.0 38  77.6  9 100 51  81.0
total 27 100 49 100  9 100 63 100
Triglycerides*
normal 13  48.1 24  49.0 >0.999  4  44.4 40  63.5 0.467
elevated (>1.7) 14  51.9 25  51.0  5  55.6 23  36.5
total 27 100 49 100  9 100 63 100
high-density lipoprotein*
normal 17  63.0 42  85.7 0.042; 0.261  5  55.6 52  82.5 0.083
lowered (<1.04) 10  37.0  7  14.3  4  44.4 11  17.5
total 27 100 49 100  9 100 63 100
Low-density lipoprotein*
normal 11  40.7 15  30.6 0.451  0   0.0 10  15.9 0.343
elevated (>3.0) 16  59.3 34  69.4  9 100 53  84.1
total 27 100 49 100  9 100 63 100
body mass index*
normal  6  22.2 19  38.8 0.003; 0.402  3  33.3 26  41.9 0.033; 0.313
overweight (>25)  7  25.9 23  46.9  1  11.1 25  40.3
obesity (>30) 14  51.9  7  14.3  5  55.6 11  17.7
total 27 100 49 100  9 100 62 100
Waist circumference*
normal  8  29.6 25  52.1 0.089  5  55.6 39  61.9 0.782
increased 19  70.4 23  47.9  4  44.4 24  38.1
total 27 100 48 100  9 100 63 100
Metabolic syndrome*
no 14  51.9 38  77.6 0.038; 0.265  5  55.6 50  79.4 0.201
yes 13  48.1 11  22.4  4  44.4 13  20.6
total 27 100 49 100  9 100 63 100
Framingham score (median, 
interquartile range)†
7.5 4-13  7 3- 11 0.524 11 4- 19  7 3- 9 0.176
*χ2 test; effect = cramer V given as the effect size for χ2 test, only for significant results.
†Mann-Whitney u test for number of diseases, effect = area under the curve (auc) as the effect size for Mann-Whitney test.
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Discussion
To our knowledge, this is the first study that investigated 
the prevalence of comorbid somatic, particularly cardio-
vascular disorders, metabolic syndrome, and elevated CRP 
in patients with recurrent major depression. Our results 
demonstrated that patients with RDD were at increased 
risk of physical, particularly cardiovascular comorbid-
ity and that the prevalence of somatic comorbidity was 
75%. In other words, physical diseases were found to be 
almost four times more frequent in depressed patients 
than in controls. This finding is similar to that of 67.1% in 
patients with bipolar disorder (9). The most common co-
morbid conditions in our RDD patients were cardiovascu-
lar disorders (46.1%), locomotor system diseases (35.5%), 
carcinoma (15.8%), thyroid diseases (9.2%), and diabetes 
(9.2%). MTB was present in 31.6% of RDD patients. This 
is in line with a study that found the prevalence of MTB 
in depressed population to be 8%-41% (10). The data on 
the relationship between depression and metabolic syn-
drome are very controversial due to inconclusive results, 
variations in study design, definitions of MTB, evaluation 
of depressive symptoms or depressive disorder, and over-
lapping of recurrent depression and bipolar II disorder 
(10-12). A systematic review and meta-analysis of epide-
miological studies indicated a bidirectional association 
between depression and metabolic syndrome (12). De-
pression is considered as a risk factor for MTB or even one 
of the components of MTB (13), while on the other hand 
MTB may be a risk factor for depression. Recently, it has 
been reported that MTB may be a mediator in the path-
way between depression and CVD (14). Elevated hs-CRP, a 
sensitive and dynamic marker for low grade systemic in-
flammation, has been recognized as a risk factor for de-
velopment and prognosis of cardiovascular diseases, car-
diovascular events in type 2 diabetes, and adverse cardiac 
events in depressed patients with CHD (7). Our results 
confirmed that patients with RDD had evidence of low 
grade systemic inflammation, which may be implicated in 
the development of comorbidities, particularly cardiovas-
cular. Elevated CRP was found to be significantly more fre-
quent in patients with RDD than in controls. Other stud-
ies also indicate an association between depression and 
increased activity of acute phase proteins and inflamma-
tory molecules, including CRP (15,16). In our study, the 
prevalence of MTB was more than two times higher in 
participants with elevated CRP than in those with nor-
mal CRP, but the difference was significant only in de-
pressed patients. It seems that inflammatory process-
es and metabolic syndrome may represent a link 
TabLe 3. Jaccard proximity measures for binarized key metabolic risk factors; only recurrent depressive disorders (RDD) patients (n = 76)
hypertension Total cholesterol LDL Triglycerides hDL hba1c bMi Metabolic syndrome cRP
Hypertension 1.00 0.19 0.19 0.18 0.00 0.16 0.21 0.28 0.18
Total cholesterol 0.19 1.00 0.81 0.54 0.13 0.30 0,.9 0.34 0.26
LDL 0.19 0.81 1.00 0.41 0.12 0.30 0.29 0.35 0.26
Triglycerides 0.18 0.54 0.41 1.00 0.22 0.21 0.36 0.47 0.27
HDL 0.00 0.13 0.12 0.22 1.00 0.17 0.23 0.28 0.29
HbA1c 0.16 0.30 0.30 0.21 0.17 1.00 0.36 0.30 0.28
BMI 0.21 0.29 0.29 0.36 0.23 0.36 1.00 0.67 0.41
Metabolic syndrome 0.28 0.34 0.35 0.47 0.28 0.30 0.67 1.00 0.34
CRP 0.18 0.26 0.26 0.27 0.29 0.28 0.41 0.34 1.00
*abbreviations: LDL – low-density lipoprotein; cRP – c-reactive protein; bMi – body mass index; hDL – high-density lipoprotein.
FiguRe 1. Prevalence of metabolic risk factors by groups 
(nRDD = 76; ncontrol = 72); error bar represents 95% confidence in-
terval; sorted by prevalence in recurrent depressive disorders 
(RDD) group. LDL – low-density lipoprotein; cRP – c-reactive 
protein; bMi – body mass index; hDL – high-density lipopro-
tein.
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between depression and different kinds of somatic co-
morbidity. Inflammation may be associated with MTB and 
its components, and MTB is sometimes even considered 
a proinflammatory state (17). Measurement of subclinical 
inflammatory markers like CRP might improve the predic-
tion of cardiovascular disease and diabetes in depressed 
patients with MTB. Our result showed that elevated CRP 
level was associated with lowered HDL and overweight/
obesity. Other studies have shown that CRP is associated 
with components of MTB, like abdominal obesity (17,18). 
Adipose tissue secretes a number of proinflammatory cy-
tokines including interleukin 6 (IL-6), which regulates he-
patic production of CRP (19). There is evidence suggest-
ing that elevated CRP may promote atherogenesis due to 
its influence on the uptake of oxidized LDL cholesterol by 
macrophages (7).
Several limitations of our study should be noted. The main 
limitation is the cross-sectional design, which cannot de-
tect the temporal changes of MTB, its components, and 
inflammation. Furthermore, our sample is relatively small 
and possibly not representative of the diverse population 
of patients with RDD. The control group comprised only 
medical personnel and future studies should include an 
additional control group of people with low professional 
stress or a group from the general population. In spite of 
its limitations, our study contributes to better understand-
ing of the association between MTB, its components, low 
grade inflammation, stress, and depression. We found 
some intriguing links between stress, depression, meta-
bolic syndrome, and low grade inflammation, which may 
be relevant to the prevalence of somatic, particularly car-
diovascular, comorbidity in patients with RDD.
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